Pharma News

WHO is establishing technical advisory group and roster of experts on digital health

  • Posted on: 14 May 2019
  • By: Shalini.Sharma

WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health.

WHO’s newly-established Digital Health Department will work to harness the power of digital health technologies and steer developments to contribute to the attainment of all people to the highest level of health through the General Programme of Work (GPW13) triple billion goals and Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages). World Health Assembly resolution WHA/71 A71 on digital health underpins this work.

EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines available in Europe safe and effective

  • Posted on: 11 May 2019
  • By: Shalini.Sharma

EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines available in Europe safe and effective.
As of today, EMA will start sharing a series of info-cards on its Twitter and LinkedIn accounts.

WHO calls for more investment in primary health care

  • Posted on: 11 May 2019
  • By: Shalini.Sharma

Primary health care is key to solving the health challenges facing countries in Asia and the Pacific, according to the World Health Organization (WHO).

WHO says that investment in primary health care is essential to provide access for the most vulnerable, build more equitable societies and help economies grow.

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

  • Posted on: 11 May 2019
  • By: Shalini.Sharma

U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ.

FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder

  • Posted on: 11 May 2019
  • By: Shalini.Sharma

The U.S. Food and Drug Administration  approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS. The only other treatment approved for LEMS is only approved for use in adults.

Anti HIV Medicine can reduce risk of HIV Acquisition

  • Posted on: 11 May 2019
  • By: admin

Pre-exposure prophylaxis (PrEP), a combination drug used to prevent HIV infection, has already gained significant traction in the U.S. and Europe. The once-a-day pill, when taken consistently, can reduce the risk of HIV acquisition by over 85 percent. A new study published in Clinical Infectious Diseases by an international research team suggests that making PrEP available to men who have sex with men (MSM) and people who inject drugs (PWID) in India may be a cost-effective way of curbing the epidemic there.

First FDA-approved vaccine for the prevention of dengue disease in endemic regions

  • Posted on: 4 May 2019
  • By: Shalini.Sharma

The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas. Dengue is endemic in the U.S. territories of American Samoa, Guam, Puerto Rico and the U.S. Virgin Islands.

FDA’s new efforts to protect women’s health and help to ensure the safety of breast implants

  • Posted on: 4 May 2019
  • By: Shalini.Sharma

There has been a growing discussion in recent months around the safety of certain breast implants, with regulatory agencies around the world weighing the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). It’s an issue that has been a priority for us at the U.S. Food and Drug Administration since 2011 when we warned women that the available information at the time indicated that there is a risk for women with breast implants, especially those with textured implants, for developing this disease.

IPA asks AIIMS not to violate recruitment rules of pharmacists

  • Posted on: 1 May 2019
  • By: PharmaTutor News

Indian Pharmacists Association (IPA) strictly opposes use of the post name Dispensing Attendant instead of Pharmacist for recent recruitment advertisement by AIIMS Rishikesh. As per IPA, the advertisement No. 2019/153 by AIIMS Rishikesh is violating Pharmacy Act and Drugs and Cosmetic rules.

Pages